Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/28—Antiandrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

• the present invention relates to inhibitors of 11 ⁇ -hydroxysteroid dehydrogenase type 1 (11 ⁇ -HSD1 ), pharmaceutical compositions thereof and methods of using the same.
• Glucocorticoids such as Cortisol (hydrocortisone) are steroid hormones that regulate fat metabolism, function and distribution, and play a role in carbohydrate, protein and fat metabolism. Glucocorticoids are also known to have physiological effects on development, neurobiology, inflammation, blood pressure, metabolism, and programmed cell death. Cortisol and other corticosteroids bind both the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which are members of the nuclear hormone receptor superfamily and have been shown to mediate Cortisol function in vivo. These receptors directly modulate transcription via DNA-binding zinc finger domains and transcriptional activation domains.
• Cortisol hydrocortisone
• glucocorticoid action was attributed to three primary factors: (1 ) circulating levels of glucocorticoid (driven primarily by the hypothalamic-pituitary-adrenal (HPA) axis); (2) protein binding of glucocorticoids in circulation; and (3) intracellular receptor density inside target tissues.
• HPA hypothalamic-pituitary-adrenal
• 11 ⁇ - hydroxysteroid dehydrogenase pre-receptor control enzymes modulate activation of GR and MR by regulation of glucocorticoid hormones.
• 11 ⁇ -HSD1 also known as 11-beta-HSD type 1 , 11 betaHSD1 , HSD11 B1 , HDL, and HSD11 L
• 11 ⁇ -HSD2 also known as 11-beta-HSD type 1 , 11 betaHSD1 , HSD11 B1 , HDL, and HSD11 L
• 11 ⁇ -HSD1 is a bi-directional oxidoreductase that regenerates active Cortisol from inactive 11-keto forms
• 11 ⁇ -HSD2 is a unidirectional dehydrogenase that inactivates biologically active Cortisol by converting it into cortisone.
• the two isoforms are expressed in a distinct tissue-specific fashion, consistent with the differences in their physiological roles.
• 11 ⁇ -HSD1 is widely distributed in rat and human tissues; expression of the enzyme and corresponding mRNA have been detected in human liver, adipose tissue, lung, testis, bone and ciliary epithelium.
• 11 ⁇ - HSD1 catalyzes both 11-beta-dehydrogenation and the reverse 11-oxoreduction reaction
• 11 ⁇ -HSD1 acts predominantly as a NADPH-dependent oxoreductase in intact cells and tissues, catalyzing the formation of active Cortisol from inert cortisone (Low et al. (1994) J. MoI. Endocrin. 13: 167-174).
• 11 ⁇ -HSD2 expression is found mainly in mineralocorticoid target tissues such as kidney (cortex and medulla), placenta, sigmoid and rectal colon, salivary gland and colonic epithelial cell lines.
• 11 ⁇ - HSD2 acts as an NAD-dependent dehydrogenase catalyzing the inactivation of Cortisol to cortisone (Albiston et al. (1994) MoI. Cell. Endocrin. 105: R11 -R17), and has been shown to protect the MR from glucocorticoid excess (e.g., high levels of receptor-active Cortisol) (Blum, et al. (2003) Prog. Nucl. Acid Res. MoI. Biol. 75:173-216). Mutations in either the 11 ⁇ -HSD1 or the 11 ⁇ -HSD2 genes result in human pathology.
• H6PD cortisone reductase deficiency
• PCOS polycystic ovary syndrome
• 11 ⁇ -HSD1 is a promising pharmaceutical target for the treatment of the metabolic syndrome (Masuzaki, et al., (2003) Curr. Drug Targets Immune Endocr. Metabol. Disord. 3: 255-62). Furthermore, inhibition of 11 ⁇ -HSD1 activity may prove beneficial in treating numerous glucocorticoid-related disorders.
• 11 ⁇ - HSD1 inhibitors could be effective in combating obesity and/or aspects of the metabolic syndrome cluster, including glucose intolerance, insulin resistance, hyperglycemia, hypertension, and/or hyperlipidemia (Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929; Morton et al. (2001 ) J. Biol. Chem. 276: 41293-41300; Morton et al. (2004) Diabetes 53: 931-938).
• inhibition of 11 ⁇ -HSD1 activity may have beneficial effects on the pancreas, including the enhancement of glucose-stimulated insulin release (Billaudel and Sutter (1979) Horm. Metab. Res. 11 : 555-560; Ogawa et al. (1992) J. Clin. Invest. 90: 497-504; Davani et al. (2000) J. Biol. Chem. 275: 34841- 34844).
• Transgenic aP2-1 1 ⁇ HSD1 mice exhibit high arterial blood pressure and have increased sensitivity to dietary salt. Moreover, plasma angiotensinogen levels are elevated in the transgenic mice, as are angiotensin Il and aldosterone; and treatment of the mice with an angiotensin Il antagonist alleviates the hypertension (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90). This suggests that hypertension may be caused or exacerbated by 11 ⁇ -HSD1 activity. Thus, 11 ⁇ -HSD1 inhibitors may be useful for treatment of hypertension and hypertension-related cardiovascular disorders.
• PAI-1 plasminogen activator inhibitor 1
• Glucocorticoids can have adverse effects on skeletal tissues; and prolonged exposure to even moderate glucocorticoid doses can result in osteoporosis (Cannalis (1996) J. Clin. Endocrinol. Metab. 81 : 3441 -3447).
• 11 ⁇ -HSD1 has been shown to be present in cultures of human primary osteoblasts as well as cells from adult bone (Cooper et al. (2000) Bone 27: 375-381 ), and the 11 ⁇ -HSD1 inhibitor carbenoxolone has been shown to attenuate the negative effects of glucocorticoids on bone nodule formation (Bellows et al. (1998) Bone 23: 119-125).
• 11 ⁇ - HSD1 is predicted to decrease the local glucocorticoid concentration within osteoblasts and osteoclasts, thereby producing beneficial effects in various forms of bone disease, including osteoporosis.
• 11 ⁇ -HSD1 inhibitors may also be useful for immunomodulation.
• glucocorticoids are perceived to suppress the immune system, in actuality, there is a complex, dynamic interaction between the HPA axis and the immune system (Rook (1999) Baillier's Clin. Endocrinol. Metabl. 13: 576-581).
• Glucocorticoids play a role in modulating the balance between cell-mediated and humoral immune response, with high glucocorticoid activity normally associated with a humoral response. Inhibition of 11 ⁇ - HSD1 therefore can be used a means of shifting the immune response towards a cell- mediated response.
• Certain disease states such as tuberculosis, leprosy (Hansen's disease) and psoriasis, trigger immune responses that are biased towards a humoral response whereas the more effective immune response may be a cell-mediated response.
• 11 ⁇ -HSD1 inhibitors may be useful for treating such diseases. It has been reported that glucocorticoids inhibit wound healing, especially in diabetic patients with ulcers (Bitar et al. (1999) J. Surg. Res. 82: 234-243; Bitar et al. (1999) Surgery 125: 594-601 ; Bitar (2000) Surgery 127: 687-695; Bitar (1998) Am. J. Pathol. 152: 547-554).
• novel compounds of the instant invention are effective inhibitors of 11 ⁇ -HSD1.
• Cy 1 is aryl, heteroaryl, monocyclic cycloalkyl or monocyclic heterocyclyl and is optionally substituted with 1 to 4 groups independently selected from fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ci-C 6 )alkyl, hydroxy(d- C 6 )alkyl, (C 3 -C 6 )cycloalkyl, hydroxy(C 3 -C 6 )cycloalkyl, (C 4 -C 7 )cycloalkylalkyl, (C 2 - C 6 )alkenyl, halo(C 2 -C 6 )alkenyl, hydroxy(C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 - C 6 )cycloalkyl(C 2 -C 4 )alkynyl, halo(d-C 6 )alkyl, hal
• R 2 is (Ci-C 6 )alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl and is optionally substituted with up to 4 groups independently selected from fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (d-C 6 )alkyl, hydroxy(d-C 6 )alkyl, (C 3 - C 6 )cycloalkyl, hydroxy(C 3 -C 6 )cycloalkyl, (C 4 -C 7 )cycloalkylalkyl, (C 2 -C 6 )alkenyl, halo(C 2 - C 6 )alkenyl, hydroxy(C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 6 )cycloalkyl(C 2 -C 4 )alkynyl, halo(Ci-C 6 )
• the first embodiment above excludes the compounds represented by structural formulas PR-36, PR-215, PR-216, PR-249, PR-251 , PR-254 and PR-689; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• Another embodiment of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising i) a pharmaceutically acceptable carrier or diluent, and ii) a compound of Formulas I, Ia 1" 20 , Ib 1"20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• Another embodiment of the invention is a method of inhibiting 11 ⁇ -HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formulas I, Ia 1"20 , Ib 1 "20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• Another embodiment of the invention is a method of treating a subject with a disease associated with the activity or expression of 11 ⁇ -HSD1 , comprising the step of administering to the subject an effective amount of a compound of Formulas I, Ia 1"20 , Ib 1 " 20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• Another embodiment of the invention is the use of a compound of Formulas I, Ia 1" 20 , Ib 1"20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for the manufacture of a medicament for inhibiting 11 ⁇ -HSD1 activity in a mammal in need of such treatment.
• Another embodiment of the invention is the use of a compound of Formulas
• Another embodiment of the invention is a compound of Formulas Formulas I, Ia 1" 20 , Ib 1"20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for use in inhibiting 11 ⁇ -HSD1 activity in a mammal in need of such treatment.
• Another embodiment of the invention is a compound of Formulas I, Ia 1"20 , Ib 1 "20 , or Ic 1"20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for use in for treating a subject with a disease associated with the activity or expression of 11 ⁇ - HSD1.
• Another embodiment of the invention is a compound of any one of Formulas Ia 1"
• the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6-dihydro-2H- pyranyl ring (i.e., all monocylic or bicyclic substructures bonded directly to Cy 1 as shown in Formulas Ia 1"20 ) is optionally substituted (substitution at ring carbons bonded to hydrogen and ring nitrogen atoms bonded to hydrogen atoms are encompassed, i.e., a "substitutable ring nitrogen atom") with up to four substituents as described above.
• suitable substituents for Cy 1 and the 1 ,3,4- oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6-dihydro-2H-pyranyl ring in Formulas Ia 1"20 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (d-C 6 )alkyl, hydroxy(d-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, hydroxy(C 3 - C 6 )cycloalkyl, (C 4 -C 7 )cycloalkylalkyl, (C 2 -C 6 )alkenyl, halo(C 2 -C 6 )
• suitable substituents for Cy 1 include (d-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )haloalkyl, (Ci-C 4 ) haloalkoxy, halogen, cyano and nitro;
• suitable substituents for a substitutable ring nitrogen atom in the 1 ,2,4-triazolyl and xanthinyl ring in Formulas Ia 4 and Ia 16 include (Ci-d)alkyl, (C 3 -C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(Ci-C 2 )alkyl, and (Ci-C 4 )haloalkyl; suitable substituents for a ring carbon atom in the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl
• R 1 is preferably methyl or ethyl.
• R 1 is preferably methyl or ethyl; and R 3 is MeSO 2 NHCH 2 CH 2 CH 2 ,
• R 1 is preferably methyl or ethyl
• R 2 is 2-hydroxy-2-methylpropyl or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (d-C 4 )alkyl, (d-C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl
• R 2 is or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (d-C 4 )alkyl, (d- C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl; and R 3 is 2-hydroxy-2-methylpropyl or 2- cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl or fluorophenyl
• R 3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl
• R 3 is 2-hydroxy-2- methylpropyl or 2-cyano-2-methylpropyl
• the substituent on the substitutable ring nitrogen atom(s) in the in the 1 ,2,4-triazolyl and xanthinyl ring in Formulas Ia 4 and Ia 16 is, independently, (Ci-C 4 )alkyl, (C 3 -C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(d-C 2 )alkyl, or (d-C 2 )haloalkyl; and each substitutable ring carbon atom in the 1 ,3,4-oxadiazolyl, 1 ,2,4- oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl,
• Another embodiment of the invention is a compound of any one of Formulas Ib 1" 20 , or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof:
• the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6- dihydro-2H-pyranyl ring (i.e., all monocylic or bicyclic substructures bonded directly to Cy 1 as shown in Formulas Ia 1"20 ) is optionally substituted (substitution at ring carbons bonded to hydrogen and at nitrogen atoms bonded to hydrogen atoms are encompassed, i.e., a "substitutable ring nitrogen atom") with up to four substituents as described above for Cy 2 .
• suitable substituents for Cy 1 and the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6- dihydro-2H-pyranyl ring in Formulas Ib 1"20 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (d-C 6 )alkyl, hydroxy(d-C6)alkyl, (C 3 - C 6 )cycloalkyl, hydroxy(C 3 -C 6 )cycloalkyl, (C 4 -C 7 )cycloalkylalkyl, (C 2 -C 6 )alkenyl, halo(C 2 - C 6 )alkenyl
• suitable substituents for Cy 1 include (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )haloalkyl, (Ci-C 4 )haloalkoxy, halogen, cyano and nitro;
• suitable substituents for a substitutable ring nitrogen atom in the 1 ,2,4- triazolyl and xanthinyl ring in Formulas Ia 4 and Ia 16 include (Ci-C 4 )alkyl, (C 3 - C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(Ci-C 2 )alkyl and (Ci-C 4 )haloalkyl; suitable substituents for a ring carbon atom in the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thieny
• the embodiments described in this paragraph exclude the compounds represented by structural formulas PR-36, PR-215, PR-216, PR-249, PR-251 , PR-254 and PR-689; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• R 1 is preferably methyl or ethyl.
• R 1 is preferably methyl or ethyl
• R 1 is preferably methyl or ethyl
• R 2 is 2-hydroxy-2-methylpropyl or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (C 1 - C 4 )alkyl, (d-C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl
• R 2 is or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (Ci-C 4 )alkyl, (Ci- C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl; and R 3 is 2-hydroxy-2-methylpropyl or 2- cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl or fluorophenyl
• R 3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl
• R 3 is 2-hydroxy-2- methylpropyl or 2-cyano-2-methylpropyl
• the substituent on the substitutable ring nitrogen atom(s) in the in the 1 ,2,4-triazolyl and xanthinyl ring in Formulas Ib 4 and Ib 16 is, independently, (Ci-C 4 )alkyl, (C 3 -C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(d-C 2 )alkyl, or (d-C 2 )haloalkyl; and each substitutable ring carbon atom in the 1 ,3,4-oxadiazolyl, 1 ,2,4- oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl,
• Another embodiment of the invention is a compound of any one of Formulas Ic 1" 20 , or a pharmaceutically acceptable salt thereof:
• the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6-dihydro-2H- pyranyl ring (i.e., all monocylic or bicyclic substructures bonded directly to Cy 1 as shown in Formulas Ia 1"20 ) is optionally substituted (substitution at ring carbons bonded to hydrogen and at nitrogen atoms bonded to hydrogen atoms are encompassed, i.e., a "substitutable ring nitrogen atom") with up to four substituents as described above in the first embodiment; suitable values for G 1 are fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy,
• n is 0, 1 , 2 or 3; suitable values for G 1 and substituents for the 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl, tetrahydrofuryl, xanthinyl, 1 ,2-diazaindolizinyl and 3,6-dihydro-2H-pyranyl ring in
• Formulas Ic 1"20 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (d-C 6 )alkyl, hydroxy(d-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, hydroxy(C 3 - C 6 )cycloalkyl, (d-d)cycloalkylalkyl, (C 2 -C 6 )alkenyl, halo(d-C 6 )alkenyl, hydroxy(C 2 - C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 6 )cycloalkyl(C 2 -d)alkynyl, halo(d-C 6 )alkyl, halo(C 3 - C 6 )cycloalkyl, halo(d-d)cycloalkylalkyl, halo(C 3 - C
• n is 0, 1 , 2 or 3;
• suitable values for G 1 include (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (C r C 4 )haloalkyl, (Ci-C 4 )haloalkoxy, halogen, cyano and nitro;
• suitable substituents for a substitutable ring nitrogen atom in the 1 ,2,4-triazolyl and xanthinyl ring in Formulas Ic 4 and Ic 16 include Ci-C 4 alkyl, (C 3 - C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(Ci-C 2 )alkyl and d-C 4 haloalkyl;
• suitable substituents for a ring carbon atom in the oxodihydropyridyl ring in Formulas Ic 1"20 include fluorine, chlorine, cyano, hydroxy, amino, (Ci-C 4 )
• the embodiments described in this paragraph exclude the compounds represented by structural formulas PR-36, PR-215, PR-216, PR-249, PR- 251 , PR-254 and PR-689; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• R 1 is preferably methyl or ethyl.
• R 1 is preferably methyl or ethyl
• R 1 is preferably methyl or ethyl
• R 2 is 2-hydroxy-2-methylpropyl or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (C 1 - C 4 )alkyl, (Ci-C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl
• R 2 is or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (Ci-C 4 )alkyl, (C 1 - C 4 )haloalkyl, and SO 2 Me
• R 1 is preferably methyl or ethyl
• R 3 is 2-hydroxy-2-methylpropyl or 2- cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl or fluorophenyl
• R 3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl
• R 3 is 2-hydroxy-2- methylpropyl or 2-cyano-2-methylpropyl
• the substituent on the substitutable ring nitrogen atom(s) in the in the 1 ,2,4-triazolyl and xanthinyl ring in Formulas Ic 4 and Ic 16 is, independently, (Ci-C 4 )alkyl, (C 3 -C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(Ci-C 2 )alkyl, or (d-C 2 )haloalkyl; and each substitutable ring carbon atom in the 1 ,3,4-oxadiazolyl, 1 ,2,4- oxadiazolyl, 1 ,2-4-triazolyl, isoxazolyl, oxazolyl, thienyl, furyl
• Another embodiment of the invention is a compound represented by any one of Formulas Id 1"6 , or a pharmaceutically acceptable salt thereof:
• G 1 is (C r C 4 )alkyl, (d-C 4 )alkoxy, (C r C 4 )haloalkyl, (C r C 4 )haloalkoxy, halogen, cyano or nitro; n is 0, 1 or 2; G 2a is hydrogen, (C 1 -C 4 )alkyl, (C 3 -C 4 )cycloalkyl or (d-C 4 )haloalkyl; G 2b is hydrogen, fluorine, chlorine, cyano, hydroxy, amino, (d-C 4 )alkyl, (C 3 -C 4 )cycloalkyl, (C 3 -C 4 )cycloalkyl(C 1 -C 2 )alkyl, halo(d-C 4 )alkyl, (Ci-C 4 )alkoxy, (C 1 - C 4 )haloalkoxy, CONH 2 , (CrC 4 )
• the embodiments described in this paragraph exclude the compounds represented by structural formulas PR-36, PR-215, PR-216, PR- 249, PR-251 , PR-254 and PR-689; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
• R 1 is preferably methyl or ethyl.
• R 1 is preferably methyl or ethyl
• R 1 is preferably methyl or ethyl
• R 2 is 2-hydroxy-2-methylpropyl or phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (C 1 - C 4 )alkyl, (C 1 -C 4 )haloalkyl and SO 2 Me
• R 1 is preferably methyl or ethyl
• R 2 is phenyl optionally substituted with 1 , 2 or 3 substituents selected from halo, cyano, CONH 2 , (d-C 4 )alkyl, (d-C 4 )haloalkyl and SO 2 Me
• R 1 is preferably methyl or ethyl; and R 3 is 2-hydroxy-2-methylpropyl or 2- cyano-2 -methylpropyl.
• R 1 is preferably methyl or ethyl; R 2 is phenyl or fluorophenyl; and R 3 is 2- hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.
• R 1 is preferably methyl or ethyl
• R 2 is phenyl
• R 3 is 2-hydroxy-2- methylpropyl
• the substituent G 2a is selected from (C 1 -C 4 )alkyl, (C 3 -C 4 )cycloalkyl, (C 3 - C 4 )cycloalkyl(C 1 -C 2 )alkyl, and (d-C 2 )haloalkyl
• G 2b is optionally selected from hydrogen, methyl and ethyl.
• alkyl means a straight or branched hydrocarbon radical having 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
• cycloalkyl means a monocyclic, bicyclic or tricyclic, saturated hydrocarbon ring having 3-10 carbon atoms and includes, for example, cyclopropyl (c- Pr), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, spiro [4.4]nonane, adamantyl and the like.
• cyclopropyl c- Pr
• cyclobutyl cyclopentyl
• cyclohexyl cycloheptyl
• cyclooctyl bicyclo[2.2.2]octyl
• bicyclo[2.2.1]heptyl bicyclo[2.2.1]heptyl
• spiro [4.4]nonane adamantyl and the like.
• aryl means an aromatic radical which is a phenyl group, a naphthyl group, an indanyl group or a tetrahydronaphthalene group.
• An aryl group is optionally substituted with 1-4 substituents.
• substituents include alkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO 2 H, CONH 2 , N- monoalkyl-substituted amido and N,N-dialkyl-substituted amido.
• heteroaryl means a 5- and 6-membered heteroaromatic radical which may optionally be fused to a saturated or unsaturated ring containing O ⁇ heteroatoms selected from N, O, and S and includes, for example, a heteroaromatic radical which is 2- or 3-thienyl, 2- or 3-furyl, 2- or 3- pyrrolyl, 2-, 3-, or 4-pyridyl, 2-pyrazinyl, 2-, A-, or 5- pyrimidinyl, 3- or 4-pyridazinyl, 1 H-indol-6-yl, 1 H-indol-5-yl, 1 H-benzimidazol-6-yl, 1 H- benzimidazol-5-yl, 2-, A-, 5-, 6-, 7- or 8-quinazolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-
• a heteroaryl is optionally substituted.
• substituents include alkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO 2 H, CONH 2 , N-monoalkyl- substituted amido and N,N-dialkyl-substituted amido, or by oxo to form an N-oxide.
• heterocyclyl means a 4-, 5-, 6- and 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
• exemplary heterocyclyls include pyrrolidine, pyrrolidin-2-one, 1- methylpyrrolidin-2-one, piperidine, piperidin-2-one, dihydropyridine, tetrahydropyridine, piperazine, 1-(2,2,2-trifluoroethyl)piperazine, 1 ,2-dihydro-2-oxopyridine, 1 ,4-dihydro-4- oxopyridine, piperazin-2-one, 3,4,5,6-tetrahydro-4-oxopyrimidine, 3,4-dihydro-4- oxopyrimidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, isoxa
• spirocycloalkyl means a cycloalkyl group which shares one ring carbon with another alkyl or cycloalkyl group.
• subject and patient may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
• the subject is a human in need of treatment.
• Certain of the disclosed compounds may exist in various stereoisomeric forms.
• Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer” means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms. The symbol “*" in a structural formula represents the presence of a chiral carbon center. “R” and “S” represent the configuration of substituents around one or more chiral carbon atoms. Thus, “R * “ and “S * " denote the relative configurations of substituents around one or more chiral carbon atoms.
• Racemate or “racemic mixture” means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light.
• “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration.
• the compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture.
• Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods.
• the stereochemistry of a disclosed compound is named or depicted by structure
• the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers.
• the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
• the compounds of the invention may be present in the form of pharmaceutically acceptable salts.
• the salts of the compounds of the invention refer to non-toxic "pharmaceutically acceptable salts.”
• Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
• Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
• Pharmaceutically acceptable acidic/anionic salts include, the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, s
• Compounds of formula I can be prepared by reaction of a ketocarbamate of formula II, wherein R D is alkyl or arylalkyl such as methyl, t-butyl or benzyl, with an organometallic reagent of formula III wherein M includes but is not limited to MgCI, MgBr, MgI or Li:
• organometallic reagent III is allylmagnesium bromide, allylzinc bromide, (2-methylallyl)magnesium chloride or (2-methoxy-2-oxoethyl)zinc bromide.
• M is MgCI, MgBr or MgI
• CeCI 3 it may be advantageous to add CeCI 3 to the reaction mixture.
• R 3 and R 2 -E can be reversed, i.e. R 3 is part of compound Il and R 2 -E is introduced via organometallic compound III.
• intermediates Il and III may be favored (in the following potential syntheses of intermediate Il only are delineated that, however, may be as well employed for the synthesis of the corresponding intermediate Il incorporating R 3 instead of R 2 -E).
• Ketocarbamates of formula Il can be prepared by reaction of aminoketones of formula IV with intermediates of formula V wherein R E is a leaving group such as chlorine, succinyloxy, imidazolyl or t-butoxycarboxy:
• Aminoketones of formula IV wherein n is preferably but not necessarily O, can be prepared by reaction of ⁇ , ⁇ -unsaturated ketones of formula Vl with amines of formula VII:
• aminoketones of formula IV can be prepared by reaction of ketones of formula VIII, wherein LG is a leaving group such as chlorine, bromine, iodine, alkyloxy, dialkylamino, wherein alkyl preferably denotes methyl, with amines of formula VII:
• Ketones of formula VIII can in turn be prepared from ⁇ , ⁇ -unsatu rated ketones of formula Vl by the formal addition of the corresponding LG-H such as HCI, HBr, HI, HOalkyl and HN(alkyl) 2 .
• LG-H such as HCI, HBr, HI, HOalkyl and HN(alkyl) 2 .
• Other methods of preparations of intermediates VIII are known in the organic chemistry literature and to the one skilled in the art.
• compounds of formula I can be prepared from compounds of general formulae I', that are in turn obtained via the same synthetic routes which are described for compounds of formula I, and Cy ⁇ M, wherein LG is a leaving group such as iodine, bromine, chlorine and trifluoromethylsulfonyloxy and M a metal or pseudo-metal containing residue such as MgCI, MgBr, MgI, B(OH) 2 , BF 3 K, B(OCH 2 CH 2 O), ZnCI, ZnBr, ZnI, SnMe 3 , Or SnBu 3 .
• LG is a leaving group such as iodine, bromine, chlorine and trifluoromethylsulfonyloxy
• M a metal or pseudo-metal containing residue such as MgCI, MgBr, MgI, B(OH) 2 , BF 3 K, B(OCH 2 CH 2 O), ZnCI, ZnBr, ZnI, SnMe 3 , Or S
• This transformation is preferably conducted with boron substituted Cy 2 as a Suzuki-Miyaura coupling reaction as described, for instance, in Example 111 of U.S. Provisional Patent Application No. 60/962,058, filed July 26, 2007.
• the entire teachings of this application are incorporated herein by reference.
• the reactivity pattern of the two coupling partners may also be reversed, i.e. Cy 1 is the nucleophilic component bearing the boron (or other metal or pseudo-metal) residue and Cy 2 is the electrophilic partner bearing the halogen or pseudo-halogen group delivering the same coupling product of formula I under identical conditions.
• Cy 1 with a leaving group can also be combined with Cy ⁇ M, wherein M denotes H, by a transition metal, preferably palladium catalyzed coupling reaction. Reactions of this type are particularly suited for heteroaromatic C/-H as detailed in e.g. ChemSusChem 2008, 1, 404-407, Eur. J. Inorg. Chem. 2008, 2550-59, J. Am.Chem. Soc. 2008, 130, 15185-92, and references quoted therein.
• a compound of formula I can also be prepared by reaction of a halo compound of formula IX, wherein Hal is chlorine or bromine, with an isocyanate in the presence of a base:
• Halo compounds of formula IX can in turn be prepared by reaction of ⁇ - haloketones of formula IX with organometallic reagents of formula III wherein M is a metal containing residue including MgCI, MgBr, MgI or Li.
• the reaction is optionally carried out in the presence of anhydrous cerium trichloride:
• the resulting solution was stirred at 0-5 0 C for 1 h and at ambient temperature for another 1.5 h.
• the solution was poured into ice-cold half-saturated aqueous NH 4 Cl solution (150 mL). After addition of dichloromethane, the mixture was filtered through Celite and was extracted with an additional portion of dichloromethane. The organic phase was separated and washed with water and dried (MgSO 4 ). The solvent was removed and the residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate 85:15->70:30) to give the title compound as a mixture of two diastereomers.
• the compound was obtained from [(S)-l-(4-bromo-phenyl)-ethyl]-(3,5-dihydroxy-5- methyl-3-phenyl-hexyl)-carbamic acid methyl ester (mixture of two diastereomers) in a mixture with 3-[(S)-I -(4-bromo-phenyl)-ethyl]-(i?)-6-(2 -hydroxy-2-methyl-propyl)-6-phenyl- [l,3]oxazinan-2-one that was resolved into the pure diastereomers by chromatography as described above.
• Tetrakis(triphenylphosphine)palladium(0) (0.20 g) was added to a mixture of copper(I) cyanide (0.87 g) and 3-[(S)-I -(4-bromo-phenyl)-ethyl]-(S)-6-(2-hydroxy-2-methyl-propyl)-6- phenyl-[l,3]oxazinan-2-one (4.00 g) in dimethylformamide (20 mL) under argon atmosphere.
• Example 2 was separated by a second chromatography on silica gel (CH 2 Cl 2 /Me0H 92:8).
• 1-Hydroxybenzotriazole (74 mg), triethylamine (0.11 mL), N-hydroxy-4- ⁇ (S)-l-[(S)-6- (2-hydroxy-2-methyl-propyl)-2-oxo-6-phenyl-[l,3]oxazinan-3-yl]-ethyl ⁇ -benzamidine (150 mg), and l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (140 mg) were added in the given order to a solution of acetic acid (21 ⁇ L) and dimethylformamide (3 mL) at room temperature. The resulting mixture was stirred at 70 0 C for 1 h and then at room temperature overnight.
• Formic-acetic acid anhydride [70 ⁇ L, prepared by stirring acetic anhydride (0.91 mL) and formic acid (0.37 mL) at 60 0 C for 1 h] was added to as solution of triethylamine (0.22 mL) and N-hydroxy-4- ⁇ (S)- 1 - [(S)-6-(2-hydroxy-2-methyl-propyl)-2-oxo-6-phenyl- [ 1 ,3 ] oxazinan-3 - yl] -ethyl ⁇ -benzamidine (200 mg)in dichloromethane (5 mL) chilled in an ice bath.
• HTRF Homogeneous Time-Resolved Fluorescence
• the incubation period for detection reaction was typically 2 hours.
• the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
• Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
• Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.
• HTRF Homogeneous Time-Resolved Fluorescence
• the incubation period for detection reaction was typically 2 hours.
• the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
• Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
• Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.
• HTRF Homogeneous Time-Resolved Fluorescence
• the incubation period for detection reaction was typically 2 hours.
• the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
• Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
• Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.
• MeMgBr (1.4 M in toluene/tetrahydrofuran, 1.1 mL) was added to a solution of (4'- ((S)- 1 - [(S)-6-(2-hydroxy-2-methyl-propyl)-2-oxo-6-phenyl- [1,3] oxazinan-3 -yl] -ethyl ⁇ -biphenyl-4- yloxy)-acetic acid methyl ester (100 mg) in tetrahydrofuran (1.5 mL) at room temperature. The resulting solution was stirred at room temperature overnight and then quenched by the addition of aqueous NH 4 Cl solution.
• HTRF Homogeneous Time-Resolved Fluorescence
• the incubation period for detection reaction was typically 2 hours.
• the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
• Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
• Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.
• LiAlH 4 (1 M solution in tetrahydrofuran, 1.16 mL) was added to a solution of 3-(4- bromo-2-oxo-2H-pyridin-l-yl)-2-methyl-propionic acid methyl ester (0.53 g) in tetrahydrofuran (6 mL) chilled in an ice bath. After stirring the solution with cooling for 2 h, another portion of LiAlH 4 (1 M in tetrahydrofuran, 0.29 mL) was added. After stirring with cooling for 1 more hour, the reaction was quenched by the addition of water. The resulting mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine and dried (MgSO 4 ). The solvent was evaporated to give the title compound.
• HTRF Homogeneous Time-Resolved Fluorescence
• the incubation period for detection reaction was typically 2 hours.
• the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
• Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
• Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.
• the compounds of the invention are useful for ameliorating or treating disorders or diseases in which decreasing the level of Cortisol is effective in treating a disease state.
• the compounds of the invention can be used in the treatment or prevention of diabetes mellitus (e.g., type Il diabetes) , obesity, symptoms of metabolic syndrome, glucose intolerance, hyperglycemica, hypertension, hyperlipidemia, insulin resistance, cardiovascular disease, dyslipidemia, atherosclerosis, lipodystrophy, osteoporosis, glaucoma, Cushing's syndrome, Addison's Disease, visceral fat obesity associated with glucocorticoid therapy, depression, anxiety, Alzheimer's disease, dementia, cognitive decline (including age-related cognitive decline), polycystic ovarian syndrome, infertility and hypergonadism.
• diabetes mellitus e.g., type Il diabetes
• obesity e.g., symptoms of metabolic syndrome, glucose intolerance, hyperglycemica, hypertension, hyperlipidemia, insulin resistance, cardiovascular disease,
• the compounds of the invention can be used as therapeutic agents for pseudo Cushing's Syndrome associated with alcoholic liver disease.
• the compounds modulate the function of B and T cells of the immune system and can therefore be used to treat diseases such as tuberculosis, leprosy and psoriasis. They can also be used to promote wound healing, particularly in diabetic patients.
• Additional diseases or disorders that are related to 11 ⁇ -HSD1 activity include those selected from the group consisting of lipid disorders, hypretriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, diabetes, coronary heart disease, stroke, peripheral vascular disease, Cushing's syndrome, hyperinsulinemia, viral diseases, and Syndrome X.
• a further disease related to 11 ⁇ -HSD1 activity is pseudo Cushing's Syndrome associated with alcoholic liver disease.
• a pharmaceutical composition of the invention may, alternatively or in addition to an 11 ⁇ -HSD1 inhibitor of the invention, comprise a pharmaceutically acceptable salt of a an 11 ⁇ -HSD1 inhibitor of the invention and one or more pharmaceutically acceptable carriers therefore.
• a pharmaceutical composition of the invention may comprise a compound of an 11 ⁇ -HSD1 inhibitor of the invention or a pharmaceutical salt thereof as the only pharmaceutically active agent in the pharmaceutical composition.
• the disclosed 11 ⁇ -HSD1 inhibitors can be used alone or in a combination therapy with one or more additional agents for the treatment of diabetes, dyslipidemia, cardiovascular disease, hypertension, obesity, cancer or glaucoma.
• the compositions of the invention are 11 ⁇ -HSD1 inhibitors.
• compositions contain compounds having a mean inhibition constant (IC 50 ) against 11 ⁇ -HSD1 of below about 1 ,000 nM; preferably below about 100 nM; more preferably below about 50 nM; even more preferably below about 5 nM; and most preferably below about 1 nM.
• IC 50 mean inhibition constant against 11 ⁇ -HSD1 of below about 1 ,000 nM; preferably below about 100 nM; more preferably below about 50 nM; even more preferably below about 5 nM; and most preferably below about 1 nM.
• the invention includes a therapeutic method for treating or ameliorating an 11 ⁇ -
• HSD1 mediated disorder in a subject in need thereof comprising administering to a subject in need thereof an effective amount of an 11 ⁇ -HSD1 inhibitor of the invention, or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof or composition thereof.
• treating or “treatment” includes both therapeutic and prophylactic treatment.
• Therapeutic treatment includes reducing the symptoms associated with a disease or condition and/or increasing the longevity of a subject with the disease or condition.
• Prophylactic treatment includes delaying the onset of a disease or condition in a subject at risk of developing the disease or condition or reducing the likelihood that a subject will then develop the disease or condition in a subject that is at risk for developing the disease or condition.
• An embodiment of the invention includes administering an 11 ⁇ -HSD1 inhibiting compound of the invention or composition thereof in a combination therapy with one or more additional agents for the treatment of diabetes, dyslipidemia, cardiovascular disease, hypertension, obesity, cancer or glaucoma.
• Agents for the treatment of diabetes include insulins, such as Humulin® (EIi Lilly), Lantus® (Sanofi Aventis), Novolin (Novo Nordisk), and Exubera® (Pfizer); PPAR gamma agonists, such as Avandia® (rosiglitizone maleate, GSK) and Actos® (pioglitazone hydrochloride, Takeda/Eli Lilly); sulfonylureas, such as Amaryl® (glimepiride, Sanofi Aventis), Diabeta® (glyburide, Sanofi Aventis), Micronase®/Glynase® (glyburide, Pfizer), and Glucot
• Agents for the treatment of dyslipidemia and cardiovascular disease include statins, fibrates, and ezetimbe.
• Agents for the treatment of hypertension include alpha- blockers, beta-blockers, calcium channel blockers, diuretics, angiotensin converting enzyme (ACE) inhibitors, dual ACE and neutral endopeptidase (NEP) inhibitors, angiotensin-receptor blockers (ARBs), aldosterone synthase inhibitors, aldosterone- receptor antagonists, or endothelin receptor antagonist.
• Agents for the treatment of obesity include orlistat, phentermine, sibutramine and rimonabant.
• An embodiment of the invention includes administering an 11 ⁇ -HSD1 inhibiting compound of the invention or composition thereof in a combination therapy with one or more other 11 ⁇ -HSD1 inhibitors, or with combination products, such as Avandamet® (metformin HCI and rosiglitazone maleate, GSK); Avandaryl® (glimepiride and rosiglitazone maleate, GSK); Metaglip® (glipizide and metformin HCI, Bristol Myers Squibb); and Glucovance® (glyburide and metformin HCI, Bristol Myers Squibb).
• Avandamet® metalformin HCI and rosiglitazone maleate, GSK
• Avandaryl® glimepiride and rosiglitazone maleate, GSK
• Metaglip® glipizide and metformin HCI, Bristol Myers Squibb
• Glucovance® glyburide and metformin HCI, Bristol Myers Squi
• the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms.
• the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
• the compounds of the present invention can be administered intranasally or transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active ingredient, either compounds or a corresponding pharmaceutically acceptable salt of a compound of the present invention.
• pharmaceutically acceptable carriers can either be solid or liquid.
• Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid which is in a mixture with the finely divided active ingredient.
• the active ingredient is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• the powders and tablets preferably contain from about one to about seventy percent of the active ingredient.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium caboxymethylcellulose, a low-melting wax, cocoa butter, and the like. Tablets, powders, cachets, lozenges, fast-melt strips, capsules and pills can be used as solid dosage forms containing the active ingredient suitable for oral administration.
• a low-melting wax such as a mixture of fatty acid glycerides or cocoa butter
• the active ingredient is dispersed homogeneously therein, as by stirring.
• the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
• Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example, water or water propylene glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
• Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.
• Aqueous suspensions for oral administration can be prepared by dispersing the finely divided active ingredient in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• the pharmaceutical composition is preferably in unit dosage form. In such form, the composition is subdivided into unit doses containing appropriate quantities of the active ingredient.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of, for example, tablets, powders, and capsules in vials or ampules. Also, the unit dosage form can be a tablet, cachet, capsule, or lozenge itself, or it can be the appropriate amount of any of these in packaged form.
• the quantity of active ingredient in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 1000.0 mg, preferably from about 0.1 mg to about 100 mg.
• the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill in the art.
• the pharmaceutical composition may contain, if desired, other compatible therapeutic agents.
• the active ingredient is preferably administered orally in a solid dosage form as disclosed above in an amount of about 0.1 mg to about 100 mg per daily dose where the dose is administered once or more than once daily.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Neurology (AREA)
• Endocrinology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Psychiatry (AREA)
• Reproductive Health (AREA)
• Child & Adolescent Psychology (AREA)
• Vascular Medicine (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Emergency Medicine (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=42097257

Family Applications (1)

Country Status (5)

Cited By (50)

Families Citing this family (7)

Citations (8)

Family Cites Families (210)

• 2010
  • 2010-02-03 JP JP2011548664A patent/JP5679997B2/ja active Active
  • 2010-02-03 CA CA2744946A patent/CA2744946A1/en not_active Abandoned
  • 2010-02-03 WO PCT/EP2010/051262 patent/WO2010089303A1/en not_active Ceased
  • 2010-02-03 EP EP10701883.0A patent/EP2393807B1/en active Active
  • 2010-02-03 US US13/147,454 patent/US8637505B2/en active Active

Patent Citations (8)

Non-Patent Citations (45)

Also Published As

Similar Documents

Legal Events